Search - tctmd.com

Displaying 441 - 460 of 491

Sort: Relevancy | Date

Presentation

Percutaneous LAA Closure with the Amplatzer Cardiac Plug in Patients with Nonvalvular A-fib and Contraindications for Anticoagulation Therapy

Presenter: M. Urena

May 28, 2013

Presentation

PROTECT AF: The Mortality Effects of LAA Closure vs. Warfarin for Stroke Prophylaxis in A-fib

Presenter: Vivek Y. Reddy

May 14, 2013

Presentation

Outcomes of Apixaban vs. Warfarin by Type and Duration of A-Fib; Results from the ARISTOTLE Trial

Presenter: Sana M. Al-Khatib

May 06, 2013

Presentation Fellows 2013

LAA Closure for Nonvalvular Atrial Fibrillation

Presenter: Mark Reisman

April 17, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

Presentation ECHO 2013

Advanced TEE: Clinical Decision Making in Cryptogenic Stroke and Atrial Fibrillation

Presenter: Marco R. Di Tullio

April 04, 2013

Presentation

Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in ‘Real-World’ Patients with A-Fib

Presenter: T.B. Larsen

March 29, 2013

Presentation

Betrixaban vs. Warfarin in A-fib Patients: Results of a Phase 2, Randomized, Dose-Ranging Study

Presenter: Stuart J. Connolly

March 28, 2013

Presentation ACC 2013

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Presenter: David R. Holmes, Jr.

March 08, 2013

Presentation

Quality-of-Life Assessment in the Randomized PROTECT AF Trial of Patients at Risk for Stroke with Nonvalvular A-fib

Presenter: 147572|Oluseun Alli

February 27, 2013

Presentation

A-fib and Aortic Stenosis: Impact on Clinical Outcomes Among Patients Undergoing TAVR

Presenter: S. Stortecky

February 10, 2013

Presentation

Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular A-fib

Presenter: Manesh R. Patel

February 03, 2013

Presentation TCT 2013

Impact of Atrial Fibrillation in Patients with STEMI Before and After Primary PCI: Insights from the HORIZONS-AMI Trial

Presenter: A. Rene, Philippe Genereux, Michael Ezekowitz, Ajay Kirtane, Roxana Mehran, Gregg Stone

January 31, 2013

Presentation TCT 2013

Cost-effectiveness Of Transcatheter Left Atrial Appendage Occlusion Compared With 5 Alternative Anticoagulation Strategies For Stroke Prevention In Atrial Fibrillation: A Markov...

Presenter: Bryan Yan, Chow Innes, Yat Yin Lam, Vivian Lee, Cheuk Man Yu

January 31, 2013

Presentation

Percutaneous Left Atrial Appendage (LAA) Closure for Stroke Prophylaxis in A-fib Patients

Presenter: Vivek Y. Reddy

January 29, 2013

Presentation

Initial Experience with a Novel Percutaneous LAA Exclusion Device in Pts with A-fib, Increased Stroke Risk, and Contraindications to Anticoagulation

Presenter: A. Massumi

January 14, 2013

Presentation TCT 2012

Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation

Presenter: Jonathan Halperin

October 25, 2012

Presentation TCT 2012

4q25 and Prediction of Atrial Fibrillation: How Can This Information Help the Clinician?

Presenter: Paddy Barrett

October 25, 2012

Presentation TCT 2012

Will Transcatheter Left Atrial Appendage Closure Transform Management of Atrial Fibrillation?

Presenter: Vivek Reddy

October 25, 2012

Presentation TCT 2012

Lone Surgical Treatment of Atrial Fibrillation: Meaningful Progress in the Past 15 Years?

Presenter: William Cohn

October 24, 2012

Advertisement

Percutaneous LAA Closure with the Amplatzer Cardiac Plug in Patients with Nonvalvular A-fib and Contraindications for Anticoagulation Therapy

PROTECT AF: The Mortality Effects of LAA Closure vs. Warfarin for Stroke Prophylaxis in A-fib

Outcomes of Apixaban vs. Warfarin by Type and Duration of A-Fib; Results from the ARISTOTLE Trial

LAA Closure for Nonvalvular Atrial Fibrillation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Advanced TEE: Clinical Decision Making in Cryptogenic Stroke and Atrial Fibrillation

Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in ‘Real-World’ Patients with A-Fib

Betrixaban vs. Warfarin in A-fib Patients: Results of a Phase 2, Randomized, Dose-Ranging Study

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Quality-of-Life Assessment in the Randomized PROTECT AF Trial of Patients at Risk for Stroke with Nonvalvular A-fib

A-fib and Aortic Stenosis: Impact on Clinical Outcomes Among Patients Undergoing TAVR

Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular A-fib

Impact of Atrial Fibrillation in Patients with STEMI Before and After Primary PCI: Insights from the HORIZONS-AMI Trial

Cost-effectiveness Of Transcatheter Left Atrial Appendage Occlusion Compared With 5 Alternative Anticoagulation Strategies For Stroke Prevention In Atrial Fibrillation: A Markov...

Percutaneous Left Atrial Appendage (LAA) Closure for Stroke Prophylaxis in A-fib Patients

Initial Experience with a Novel Percutaneous LAA Exclusion Device in Pts with A-fib, Increased Stroke Risk, and Contraindications to Anticoagulation

Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation

4q25 and Prediction of Atrial Fibrillation: How Can This Information Help the Clinician?

Will Transcatheter Left Atrial Appendage Closure Transform Management of Atrial Fibrillation?

Lone Surgical Treatment of Atrial Fibrillation: Meaningful Progress in the Past 15 Years?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content